Mark J Foley
CIK 1529196 · President & CEO · last filed 2026-06-23
Mark J Foley is a President & CEO who has filed 129 SEC Form 4 insider transactions across 4 companies since 2012. The most recent filing, for GKOS, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$30.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$10.10M
4
129
-$30.04M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| GKOS | Director | 60,267 | $164.85 | $9.94M | -$2.92M | 19 | 2026-06-23 |
| Revance Therapeutics, Inc. (RVNC) Delisted | President & CEO | 27,933 | $3.65 | $102.0K | -$5.60M | 34 | 2025-02-06 |
| SIBN | Director | 8,797 | $18.52 | $163.0K | $0 | 2 | 2020-06-18 |
| Zeltiq Aesthetics Inc (ZLTQ) Delisted | President and CEO | 0 | — | — | -$21.52M | 67 | 2017-04-28 |
Recent Filings
129 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-23 | GKOS | Grant (A) | — | $0 | EDGAR |
| 2026-06-01 | GKOS | Grant (A) | +1,878 | $0 | EDGAR |
| 2026-01-07 | GKOS | Grant (A) | +1,168 | $0 | EDGAR |
| 2025-06-02 | GKOS | Grant (A) | +2,972 | $0 | EDGAR |
| 2025-02-28 | GKOS | Mixed | +19,313 | -$1.33M | EDGAR |
| 2025-02-26 | GKOS | Notice (144) | −20,687 | -$2.50M | EDGAR |
| 2025-02-06 | Revance Therapeutics, Inc. (RVNC) Delisted | Mixed | −1,135,781 | -$4.04M | EDGAR |
| 2025-02-05 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +27,933 | $0 | EDGAR |
| 2025-01-03 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +1,000 | $2.2K | EDGAR |
| 2024-07-02 | Revance Therapeutics, Inc. (RVNC) Delisted | Grant (A) | +1,000 | $2.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.